Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
157
resultados
Última actualización
26/09/2025 [07:31:00]
Resultados 75 a 100 de 157
Resumen de: US2025268982A1
Non-aggregating protein analogues of proteins involved in a proteinopathy, for example Alzheimer's disease, are provided. The protein has a beta-sheet aggregation domain, and the non-aggregating protein analogue has a beta-sheet destabilizing modification in the beta-sheet aggregation domain but substantially retains wild type protein function. The beta-sheet destabilizing modification can be a substitution of a naturally occurring amino acid for a non-naturally occurring amino acid. Methods of treating a proteinopathy using the non-aggregating protein analogues and methods of designing a non-aggregating protein analogue are provided.
Resumen de: US2025268981A1
The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
Resumen de: US2025268952A1
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
Resumen de: US2025268946A1
The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Resumen de: US2025270618A1
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
Resumen de: US2025270547A1
The present invention relates to a trans-splicing ribozyme specific to Alzheimer's disease, and a use thereof. The trans-splicing ribozyme replaces RNA of genes that cause or increase the risk of Alzheimer's disease with RNA of genes that are beneficial for the treatment of the disease, thereby reducing the expression of the disease-causing genes and increasing the expression of the genes beneficial for the treatment of the disease, and thus can be usefully used to prevent or treat Alzheimer's disease.
Resumen de: US2025270565A1
Embodiments of the present disclosure pertain to methods of treating or preventing a neurological disorder in a subject by administering to the subject at least one microRNA (miR-NA), at least one inhibitor of the miRNA, or combinations thereof. Additional embodiments of the present disclosure pertain to compositions that include at least one miRNA of the present disclosure, at least one inhibitor of the miRNAs of the present disclosure, or combinations thereof. In some embodiments, the composition is suitable for use in treating or preventing a neurological disorder in a subject.
Resumen de: US2025270159A1
A 1-(cyclobutylidenemethyl)-2,4,5-trimethoxybenzene compound and a preparation method and use thereof are provided, belonging to the field of drug development technology. The prepared 1-(cyclobutylidenemethyl)-2,4,5-trimethoxybenzene compound may be used for the preparation of an antiepileptic drug and drugs for treatment and/or prevention of traumatic craniocerebral injury disorders, ischemic stroke, hemorrhagic stroke, and Parkinson's disease.
Resumen de: US2025270303A1
Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.
Resumen de: WO2025179301A1
Embodiments are directed to methods for treating neurodegenerative disease by administering anti-viral compounds to subjects having or at risk of developing neurodegenerative diseases such as Alzheimer's disease.
Resumen de: WO2025179300A1
Methods, compositions, and kits are capable of detecting, identifying, diagnosing, prognosing, assessing, monitoring, and/or treating a neurological injury such as acute TBI and distinguishing geriatric TBI from conditions such as dementia, Alzheimer's Disease, Parkinson's disease and the like. Also disclosed are methods of testing elderly patients who have or are suspected of having traumatic brain injury using panels of biomarkers that distinguish TBI from dementia, and, optionally, treating such patients for TBI or dementia based upon the results of the biomarker tests.
Resumen de: WO2025179044A1
A self-inactivating CRISPR/Cas9 delivery system utilizing a dual vector system may be provided. A first viral vector includes an expression unit for expression of a Cas9 nuclease and a nucleotide sequence encoding an sgRNA targeting a specific genomic locus. The second viral vector includes a nucleotide sequence encoding an sgRNA targeting expression of the Cas9 nuclease by the expression unit. The self-inactivating CRISPR/Cas9 dual vector delivery system can be used for treating a genetic gene-associated disease/disorder and/or a sporadic gene-associated disease/disorder. In embodiments, the disease and/or disorder may be a neurological disease and/or disorder. In embodiments, neurological disease and/or disorder may be Huntington's disease. Methods of treatment, medicaments, and pharmaceutical compositions may be provided.
Resumen de: WO2025175626A1
Provided are a probiotic formulation for preventing or treating Alzheimer's disease and use thereof. The microorganisms in the probiotic formulation consist of Akkermansia muciniphila and Bifidobacterium breve. Akkermansia muciniphila and Bifidobacterium breve can coordinate with each other after being compounded, so as to provide a synergistic effect on alleviating Alzheimer's disease and thereby a new strategy for preventing or treating Alzheimer's disease. Since Akkermania muciniphila and Bifidobacterium breve are both probiotics, a related functional product prepared from Akkermania muciniphila and Bifidobacterium breve may feature good safety and less likelihood of inducing resistance.
Resumen de: US2025270301A1
The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.
Resumen de: US2025268879A1
The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
Resumen de: US2025268911A1
Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70-140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ≤23 and/or a CDR-SOB score of ≥4.5.
Resumen de: US2025268859A1
The invention concerns a compound of formula (I) (I) R1═H, —CH3 or acyl group, preferably R1═—CH3R2═H or halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2═H or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating neurodegenerative diseases when central muscarinic neurotransmission is compromised, wherein said neurodegenerative disease is selected in the group consisting of Alzheimer's Disease (AD), vascular dementia, Dementia with Lewy bodies (DLB), mixed dementia, frontotemporal lobar degeneration (FTLD), and Parkinson's disease (PD).
Resumen de: CN119998661A
In a first aspect, the present invention relates to a method for identifying a subject suffering from or at risk of developing Alzheimer's dementia (AD), the method comprising: (a) determining in a first bodily fluid sample of the subject at least an amount of a compound having a mass of 110.0367 in grams/mole; (b) determining an amount of the same compound as in (a) in a second body fluid sample of the subject; (c) determining a change in the amount of the compound determined according to (a) compared to the corresponding amount of the compound determined according to (b); (d) analyzing the change determined in (c) using a computer-implemented prediction algorithm capable of predicting AD in the subject based on the compound, thereby identifying a subject having AD or at risk of developing Alzheimer's dementia if AD is predicted; wherein the first body fluid sample is obtained prior to administration of thietherazine or a pharmaceutically acceptable salt thereof, and the second body fluid sample is obtained after administration of thietherazine or a pharmaceutically acceptable salt thereof to the subject.
Resumen de: EP4606386A2
In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a GUCY2C agonist. The invention also relates to test systems and cells that are suited to identify new candidate compounds for the treatment of Parkinson's disease.
Resumen de: WO2025173839A1
The present invention relates to: an albumin-immobilized cellulose; and a composition for treating Alzheimer's disease, the composition comprising the albumin-immobilized cellulose. More specifically, the present invention relates to an albumin (human serum albumin, HSA)-immobilized cellulose having excellent amyloid beta (Aβ) adsorption capacity, and a composition for treating Alzheimer's disease by using an in vitro amyloid beta (Aβ) trap, wherein the composition comprises the albumin-immobilized cellulose.
Resumen de: WO2025173839A1
The present invention relates to: an albumin-immobilized cellulose; and a composition for treating Alzheimer's disease, the composition comprising the albumin-immobilized cellulose. More specifically, the present invention relates to an albumin (human serum albumin, HSA)-immobilized cellulose having excellent amyloid beta (Aβ) adsorption capacity, and a composition for treating Alzheimer's disease by using an in vitro amyloid beta (Aβ) trap, wherein the composition comprises the albumin-immobilized cellulose.
Resumen de: AU2024220263A1
Provided herein are compounds, pharmaceutical compositions, and methods of use for selectively reducing the amount or activity of HTT RNA comprising SNP rs7685686 in a cell or subject, and in certain instances reducing the amount of mutant HTT protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of Huntington's disease.
Resumen de: US2025262260A1
The present disclosure provides use of a turnip extract in the preparation of a drug for the prevention and treatment of Alzheimer's disease, which belongs to the technical field of biomedicine. The turnip extract of the present disclosure has good activity against Alzheimer's disease and has good application prospects in a drug for the prevention and treatment of Alzheimer's disease.
Resumen de: US2025262230A1
As described herein, inhibitors of High mobility group box protein 1 (HMGB1) can significantly reduce HMGB1 nucleo-cytoplasmic translocation, gliosis, neurodegeneration, Tau pathologies, and myelin deficits, especially in subjects having an AP0E4 allele. Methods are therefore described herein that include administering one or more inhibitors of High mobility group box protein 1 (HMGB1) to a subject having at least one genomic AP0E4 allele.
Nº publicación: WO2025175135A1 21/08/2025
Solicitante:
YALE UNIV [US]
YALE UNIVERSITY
Resumen de: WO2025175135A1
Provided herein are compositions and methods of treating and/or preventing Parkinson's Disease (PD) in a subject in need thereof, the methods including administering an agent that increases, enhances, and/or stimulates Kcnn1 expression or activity.
BOPI
Sede Electrónica
